| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Celyad Oncology SA (NASDAQ: CYAD)
CYAD Technical Analysis
5
| As on 9th Jun 2023 CYAD SHARE Price closed @ 0.39 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.20 & Strong Sell for SHORT-TERM with Stoploss of 3.54 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CYADSHARE Price
| Open | 0.49 | Change | Price | % |
| High | 0.53 | 1 Day | 0.00 | 0.00 |
| Low | 0.39 | 1 Week | 0.11 | 39.29 |
| Close | 0.39 | 1 Month | -0.32 | -45.07 |
| Volume | 6869 | 1 Year | -3.78 | -90.65 |
| 52 Week High 4.17 | 52 Week Low 0.15 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CYAD Daily Charts |
CYAD Intraday Charts |
Whats New @ Bazaartrend |
CYAD Free Analysis |
|
|
CYAD Important Levels Intraday
| RESISTANCE | 0.66 |
| RESISTANCE | 0.57 |
| RESISTANCE | 0.52 |
| RESISTANCE | 0.47 |
| SUPPORT | 0.31 |
| SUPPORT | 0.26 |
| SUPPORT | 0.21 |
| SUPPORT | 0.12 |
CYAD Forecast April 2024
| 4th UP Forecast | 1.99 |
| 3rd UP Forecast | 1.48 |
| 2nd UP Forecast | 1.16 |
| 1st UP Forecast | 0.84 |
| 1st DOWN Forecast | -0.06 |
| 2nd DOWN Forecast | -0.38 |
| 3rd DOWN Forecast | -0.7 |
| 4th DOWN Forecast | -1.21 |
CYAD Weekly Forecast
| 4th UP Forecast | 1.16 |
| 3rd UP Forecast | 0.91 |
| 2nd UP Forecast | 0.76 |
| 1st UP Forecast | 0.61 |
| 1st DOWN Forecast | 0.17 |
| 2nd DOWN Forecast | 0.02 |
| 3rd DOWN Forecast | -0.13 |
| 4th DOWN Forecast | -0.38 |
CYAD Forecast2024
| 4th UP Forecast | 8.19 |
| 3rd UP Forecast | 5.69 |
| 2nd UP Forecast | 4.14 |
| 1st UP Forecast | 2.6 |
| 1st DOWN Forecast | -1.82 |
| 2nd DOWN Forecast | -3.36 |
| 3rd DOWN Forecast | -4.91 |
| 4th DOWN Forecast | -7.41 |
Celyad Oncology SA ( NASDAQ USA Symbol : CYAD )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CYAD Business Profile
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium. Address: Axis Business Park, Mont-Saint-Guibert, Belgium, 1435
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service